What are the recommended treatment regimens for cryptococcal infection?

Treatment of Cryptococcal Infection

For cryptococcal meningoencephalitis, the gold standard induction therapy is amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for at least 2 weeks, followed by fluconazole (400 mg/day) for a minimum of 8 weeks 1.

Treatment Strategy by Clinical Presentation

CNS Disease (Meningoencephalitis)

Primary Induction Regimen (Highest Level Evidence - A-I):

• Amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV PLUS flucytosine 100 mg/kg/day orally (divided into 4 doses) for at least 2 weeks
• Followed by fluconazole 400 mg/day orally for minimum 8 weeks (consolidation phase) 1

Important modification: Recent high-quality evidence from sub-Saharan Africa demonstrates that one week of amphotericin B plus flucytosine followed by fluconazole on days 8-14 is superior to the traditional 2-week regimen, with significantly lower 10-week mortality (RR 0.62,95% CI 0.42-0.93) and reduced risk of severe anemia 2. This shortened regimen achieved the lowest 10-week mortality (24.2%) in network meta-analysis 3.

For patients with or at risk of renal dysfunction:

• Substitute lipid formulations: liposomal amphotericin B (3-4 mg/kg/day IV) or amphotericin B lipid complex (5 mg/kg/day IV) for at least 2 weeks 1
• This is particularly critical in organ transplant recipients, where amphotericin B deoxycholate should be used with extreme caution due to nephrotoxicity risk 1

Alternative Regimens (in descending order of recommendation):

1. Amphotericin B monotherapy (any formulation) for 4-6 weeks - use when flucytosine unavailable 1

2. Amphotericin B deoxycholate (0.7 mg/kg/day) plus fluconazole (800 mg/day) for 2 weeks, then fluconazole 800 mg/day for minimum 8 weeks 1

3. All-oral regimen: Fluconazole (≥800 mg/day, preferably 1200 mg) plus flucytosine (100 mg/kg/day) for 6 weeks - this is a viable option when amphotericin B cannot be safely administered 1, 3, 2

4. Fluconazole monotherapy (800-2000 mg/day, encourage ≥1200 mg/day) for 10-12 weeks - least preferred option 1

HIV-Specific Considerations

Timing of antiretroviral therapy:

• Initiate HAART 2-10 weeks after starting antifungal treatment (not immediately) 1
• This delay reduces risk of immune reconstitution inflammatory syndrome (IRIS)

Maintenance therapy discontinuation:

• Consider stopping suppressive fluconazole when CD4 count >100 cells/μL AND undetectable/very low HIV RNA sustained for ≥3 months (after minimum 12 months total antifungal therapy) 1
• Reinstitute if CD4 drops below 100 cells/μL 1

Asymptomatic antigenemia:

• Perform lumbar puncture and blood culture
• If positive, treat as symptomatic meningoencephalitis
• If negative for CNS disease, treat with fluconazole 400 mg/day until immune reconstitution 1

Organ Transplant Recipients

CNS disease:

• Prefer lipid formulations over amphotericin B deoxycholate due to nephrotoxicity concerns
• Liposomal amphotericin B (3-4 mg/kg/day) or ABLC (5 mg/kg/day) PLUS flucytosine (100 mg/kg/day in 4 doses) for at least 2 weeks
• Followed by fluconazole 400-800 mg/day for 8 weeks, then 200-400 mg/day for 6-12 months 1
• Critical: Reduce immunosuppression sequentially, lowering corticosteroids first 1

Pulmonary Cryptococcosis

Immunosuppressed patients:

• Always rule out CNS involvement with lumbar puncture - presence of meningitis changes entire treatment approach 1
• Severe pneumonia or disseminated disease: treat as CNS disease 1
• Mild-to-moderate symptoms without diffuse infiltrates: fluconazole 400 mg/day for 6-12 months 1

Non-immunosuppressed patients:

• Mild-to-moderate: fluconazole 400 mg/day for 6-12 months 1
• Severe disease: treat as CNS disease 1
• Lumbar puncture consideration: Can be avoided in normal hosts with asymptomatic pulmonary nodule/infiltrate, no CNS symptoms, and negative or very low serum cryptococcal antigen 1, 4

Disseminated Non-CNS Disease

High fungal burden (cryptococcal antigen titer ≥1:512) or multiple noncontiguous sites:

• Treat as CNS disease even without meningitis 1

Single site, no fungemia, no immunosuppression, CNS ruled out:

• Fluconazole 400 mg/day for 6-12 months 1

Critical Management Pitfalls

Increased intracranial pressure:

• This is a major cause of mortality and requires aggressive management with serial lumbar punctures
• The guidelines emphasize this as a critical factor for successful management 1

Drug toxicity monitoring:

• Amphotericin B: Monitor renal function closely, especially in transplant recipients
• Flucytosine: Monitor for bone marrow suppression (anemia, leukopenia)
• The one-week amphotericin B regimen significantly reduces severe anemia risk (RR 0.31) compared to two weeks 2

Flucytosine availability:

• When unavailable, extend amphotericin B duration to 4-6 weeks OR use combination amphotericin B plus fluconazole 1
• The all-oral fluconazole plus flucytosine regimen is an effective alternative when amphotericin B cannot be used 3, 2

Emerging Evidence

Recent research demonstrates that single-dose high-dose liposomal amphotericin B (10 mg/kg) shows noninferior early fungicidal activity compared to 14 days of standard dosing 5, though this requires phase 3 validation. Additionally, short-duration liposomal amphotericin B (≤1 week) may have comparable outcomes to longer durations in resource-rich settings 6, but the evidence base from these settings remains limited.

The strength of evidence consistently supports amphotericin B plus flucytosine as superior to amphotericin B plus fluconazole (10-week mortality hazard ratio 0.62,95% CI 0.45-0.84) 2, making flucytosine the preferred partner drug when available.